Cooperative Agreement U01DE034109
- This federal Project Grant award of $249,000.00, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to develop a novel patient-derived tumor organoid (tumoroid) platform for precision treatment of head and neck squamous cell carcinomas (HNSCCS). The key products and services to be delivered include: Establishing a high-throughput automated HNSCC tumoroid platform to capture tumor...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,277,806 Cooperative Agreement under the Oral Diseases and Disorders Research (CFDA 93.121) program to The Washington University to validate a novel prognostic biomarker for oropharyngeal cancer (OPC). The project aims to validate a biomarker called HPVHET that captures tumor biology and heterogeneity in over 1,000 diverse human papillomavirus-positive (HPV+) OPC patients. The goals are to analytically validate the...
- The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $716,123 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Florida. The grant, awarded on September 8, 2025, aims to establish a clinical cohort and develop novel analytical methodologies to validate, discover, and optimize non-invasive liquid biopsy tests for prognosis prediction in head and...
- This federal Project Grant award of $1,899,042.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research at the University of Pittsburgh to analyze high-dimensional genomic datasets to reveal mechanistic insights on divergent outcomes of head and neck cancer. The project aims to use existing public databases of human head and neck squamous cell carcinomas (HNSCC) to identify new mechanisms...
- This federal Project Grant award of $483,360.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will fund research to target vulnerabilities in the EGFR/HER3/HER2 oncogenic signaling circuitry for developing new precision therapies for oral cancer. The project aims to explore synthetic lethal and gene interaction networks to expose druggable systems vulnerabilities and uncover mechanisms of...
- This $681,331 Cooperative Agreement award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, supports a clinical trial to test the effectiveness of an intensive preventive dental program administered in oncology practices to reduce dental disease and improve oral health-related quality of life in head and neck cancer patients receiving radiation therapy. The key products and services to be delivered under...
- This federal Project Grant award of $3,742,682 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Massachusetts. The grant supports research to dissect the role of the chemokine CCL5 in shaping antigen-specific T cell responses against head and neck cancers. Key objectives include: Investigating how CCL5 chemokine networks impact the development...
- This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $156,000 Project Grant under the Oral Diseases and Disorders Research (CFDA 93.121) federal grant program to the University of Colorado-Denver. The grant will support a research project titled "Sex-Specific Immune Microenvironment in Oral Cancer" from July 1, 2025 to June 30, 2027. The research aims to investigate sex-specific differences in the immune microenvironment of head and neck squamous cell...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $390,000 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to The Medical College of Wisconsin, Inc. The grant funds a 5-year research project to leverage single-cell co-culture and gene expression profiling to identify tumor antigen-specific T cells in oral squamous cell carcinoma (OSCC). The project aims to develop innovative methods to isolate and characterize tumor-infiltrating...
This Cooperative Agreement award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $702,871 to The Washington University in Missouri to conduct research validating a "hybrid epithelial/mesenchymal state" biomarker for predicting treatment response and outcomes in head and neck cancer. The award period runs from August 2025 to May 2030. The key objectives are to: 1) validate an RNA-sequencing-based "hybrid epithelial/mesenchymal state" heterogeneity score to predict outcomes in a diverse cohort of 400 treatment-naïve oral cavity squamous cell carcinoma patients, including 150 Black Americans; and 2) investigate if this biomarker can also predict outcomes in the recurrent/metastatic setting where tissue sampling may be limited. This research aims to advance understanding of the complex interplay between malignant, immune, and stromal cells driving tumor invasion and metastasis in head and neck cancers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $702.9k | 8/8/25 |